Crescent Biopharma, Inc. (NASDAQ: CBIO) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
16.38
+1.51+10.15%
News
Up 10.2% — Crescent Biopharma Announces Grants of Inducement Awards (globenewswire.com).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 27.57M | Perf Week | -0.36% |
| Market Cap | 451.63M | Forward P/E | - | EPS next Y | -2.84 | Insider Trans | 2.80% | Shs Float | 21.32M | Perf Month | -3.42% |
| Enterprise Value | 280.63M | PEG | - | EPS next Q | -0.67 | Inst Own | - | Short Float | 17.55% | Perf Quarter | -8.59% |
| Income | -154.00M | P/S | 41.06 | EPS this Y | - | Inst Trans | - | Short Ratio | 11.02 | Perf Half Y | 66.80% |
| Sales | 11.00M | P/B | 2.77 | EPS next Y | -5.07% | ROA | -76.76% | Short Interest | 3.74M | Perf YTD | 38.11% |
| Book/sh | 5.91 | P/C | 2.63 | EPS next 5Y | - | ROE | -84.16% | 52W High | 27.41 -40.24% | Perf Year | 36.50% |
| Cash/sh | 6.24 | P/FCF | - | EPS past 3/5Y | - | ROIC | -102.29% | 52W Low | 8.72 87.84% | Perf 3Y | -90.01% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - 1.92% | Gross Margin | - | Volatility | 9.59% 8.23% | Perf 5Y | -91.89% |
| Dividend TTM | - | EV/Sales | 25.51 | EPS Y/Y TTM | -380.00% | Oper. Margin | -1417.74% | ATR (14) | 1.41 | Perf 10Y | -98.10% |
| Dividend Ex-Date | - | Quick Ratio | 9.66 | Sales Y/Y TTM | - | Profit Margin | -1180.57% | RSI (14) | 50.71 | Recom | 2.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.66 | EPS Q/Q | 84.99% | SMA20 | 3.29% | Beta | 1.23 | Target Price | 29.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -5.39% | Rel Volume | 0.74 | Prev Close | 14.87 |
| Employees | 44 | LT Debt/Eq | 0.00 | Earnings | Nov 05 | SMA200 | 9.75% | Avg Volume | 349.78K | Price | 16.38 |
| IPO Date | Jan 10, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -0.58% 180.00% | Net Debt/EBITDA | 1.03 | Volume | 258,791 | Change | 10.15% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-01-26 | Downgrade | HC Wainwright & Co. | Buy → Neutral | |
| Feb-26-26 | Reiterated | Stifel Nicolaus | Buy | $32 → $29 |
| Jan-28-26 | Initiated | Piper Sandler | Overweight | $35 |
| Jan-21-26 | Initiated | Guggenheim | Buy | $35 |
| Dec-04-25 | Reiterated | Stifel Nicolaus | Buy | $28 → $32 |
| Aug-25-25 | Initiated | Jefferies | Buy | $26 |
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold | |
| May-06-24 | Downgrade | HC Wainwright & Co. | Buy → Neutral | |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy | |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
Latest News
Aug-03-26
Jul-30-26
07:35AM
Jul-23-26
Jul-16-26
Jul-16-2604:01PM
Jul-14-26
Jul-14-2609:45PM
04:02PM
04:01PM
Jul-01-26
Company
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 11 | 0 | 0 | 0 | 1 | 10 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Gross Profit | 11 | 0 | 0 | 0 | 1 | 0 | -1 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 25 | 16 | 19 | 19 | 17 | 17 | 14 | 11 | 10 | |
| Research and Development | 138 | 28 | 20 | 28 | 47 | 45 | 47 | 40 | 24 | |
| Other Operating Expense | 0 | 6 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | |
| Operating Income | -153 | -50 | -39 | -47 | -63 | -52 | -61 | -52 | -34 | |
| Interest Expense | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 3 | 2 | 2 | 1 | 0 | 0 | 3 | 3 | 1 | |
| Net Income Before Taxes | -152 | -49 | -37 | -47 | -63 | -51 | -58 | -48 | -33 | |
| Income Taxes | 2 | 0 | 0 | 0 | 0 | 0 | -4 | 3 | 0 | |
| Consolidated Net Income | -154 | -49 | -37 | -47 | -63 | -51 | -54 | -48 | -33 | |
| Net Income From Continuing Operations | -154 | -49 | -37 | -47 | -63 | -51 | -58 | -48 | -33 | |
| Net Income | -154 | -49 | -37 | -47 | -63 | -51 | -54 | -48 | -33 | |
| EPS (Recurring) | -14.78 | -1.40 | -0.58 | -0.89 | -1.23 | -1.12 | -1.34 | -1.18 | -1.13 | |
| EPS (Basic, Before Extraordinaries) | -14.78 | -1.40 | -0.58 | -0.89 | -1.23 | -1.12 | -1.34 | -1.18 | -1.13 | |
| EPS (Diluted) | -14.78 | -1.40 | -0.58 | -0.89 | -1.23 | -1.12 | -1.34 | -1.18 | -1.13 | |
| EBITDA | -150 | -44 | -39 | -47 | -63 | -51 | -57 | -51 | -34 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 10.78 | — | — | — | 7,344.00 | 1,729.60 | — | — | — | |
| Gross Margin | 100.00 | — | — | — | 100.00 | 0.00 | — | — | — | |
| Operating Margin | -1,390.91 | — | — | — | -6,300.00 | -520.00 | — | — | — | |
| Net Margin | -1,400.00 | — | — | — | -6,300.00 | -510.00 | — | — | — | |
| Shares Outstanding | 10 | 20 | 63 | 53 | 51 | 46 | 43 | 41 | 29 | |
| Market Capitalization | 119 | 498 | 14,868 | 16,059 | 7,344 | 17,296 | 22,747 | 38,827 | 48,691 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | director, 10 percent owner: | Jul 16 '26 | Buy | 8.97 | 1,379,347 | 12,375,551 | 3,601,316 | Jul 20 |
| Brumm Joshua T | Chief Executive Officer | Jun 22 '26 | Sale | 17.99 | 42,305 | 761,067 | 281,212 | Jun 23 |
| Lynch Ryan | See Remarks | Jun 22 '26 | Sale | 17.99 | 465 | 8,365 | 13,871 | Jun 23 |
| Pinkas Jan | Chief Scientific Officer | Jun 22 '26 | Sale | 17.99 | 1,288 | 23,171 | 22,239 | Jun 23 |
| Scalzo Richard William | Chief Financial Officer | Jun 22 '26 | Sale | 17.99 | 1,112 | 20,005 | 20,298 | Jun 23 |
| Im Ellie Eunkyung | Chief Medical Officer | Jun 22 '26 | Sale | 17.99 | 1,219 | 21,930 | 22,069 | Jun 23 |
| Bispham Barbara Harlin | See Remarks | Jun 22 '26 | Sale | 17.99 | 1,218 | 21,912 | 19,330 | Jun 23 |
| McNeill Jonathan | President and COO | Jun 22 '26 | Sale | 17.99 | 20,549 | 369,677 | 139,158 | Jun 23 |
| Fairmount Funds Management LLC | director, 10 percent owner: | Dec 04 '25 | Buy | 12.23 | 1,491,434 | 18,237,731 | 2,747,866 | Dec 08 |
| Invus Public Equities, L.P. | 10% Owner | Aug 08 '24 | Sale | 0.19 | 260,873 | 50,009 | 6,317,565 | Aug 09 |
| Invus Public Equities, L.P. | 10% Owner | Aug 07 '24 | Sale | 0.18 | 61,488 | 11,197 | 6,578,438 | Aug 09 |
| Invus Public Equities, L.P. | 10% Owner | Aug 06 '24 | Sale | 0.18 | 55,732 | 10,188 | 6,639,926 | Aug 07 |
| Invus Public Equities, L.P. | 10% Owner | Aug 05 '24 | Sale | 0.19 | 164,523 | 30,996 | 6,695,658 | Aug 07 |
| Invus Public Equities, L.P. | 10% Owner | Aug 02 '24 | Sale | 0.20 | 286,200 | 57,354 | 6,860,181 | Aug 05 |
| Invus Public Equities, L.P. | 10% Owner | Aug 01 '24 | Sale | 0.22 | 63,564 | 13,743 | 7,146,381 | Aug 05 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.